Prepregnancy duration of dopamine agonist treatment (particularly for longer than 1 year), small tumors, and lower prolactin levels before pregnancy reduce the risk of tumor growth and increase the chance of tumor regression after pregnancy and lactation. This evidence concerns the gene PRL and neoplasm.